Article
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial.
Hepatology (Baltimore, Md.) - 1 Jan 2008
Mangia Alessandra, Minerva Nicola, Bacca Donato, Cozzolongo Raffaele, Ricci Giovanni L, Carretta Vito, Vinelli Francesco, Scotto Gaetano, Montalto Giuseppe, Romano Mario, Cristofaro Giuseppe, Mottola Leonardo, Spirito Fulvio, Andriulli Angelo
Abstract excerpt
UNLABELLED: It was hypothesized that in hepatitis C virus (HCV) genotype 1 patients, variable treatment duration individualized by first undetectable HCV RNA is as effective as standard 48-week treatment. Patients (n = 696) received peginterferon alfa-2a, 180 mg/week, or peginterferon alfa-2b, 1.5 mg/kg/week, plus ribavirin, 1000-1200 mg/day, for 48 weeks (standard, n = 237) or for 24, 48, or 72 weeks if...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.